TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company and global provider of life science reagents and ...

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...

Scientists at IOCB Prague are uncovering new details of gene transcription. They have identified a previously unknown molecular mechanism by which the transcription of genetic information from ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...

This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...

In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.

SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols™ ExTend Cap AU, ...

The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The influenza virus continues to pose a threat to our health. It triggers seasonal ...